Edition:
United States

Profile: Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

577.60INR
5:24am EST
Change (% chg)

Rs-2.75 (-0.47%)
Prev Close
Rs580.35
Open
Rs583.80
Day's High
Rs592.50
Day's Low
Rs574.40
Volume
1,100,568
Avg. Vol
1,261,668
52-wk High
Rs617.80
52-wk Low
Rs457.45

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.

Company Address

Cipla Ltd

Mumbai Central
MUMBAI     400013
P: +9122.24826000
F: +9122.24826893

Company Web Links